Coalition for Epidemic Preparedness Innovations

Fondazione Biotecnopolo di Siena is a private, non-profit foundation with a registered office and operations to develop applied research and innovation in the field of biotechnology and life sciences.

Micron Biomedical is a clinical-stage biopharmaceutical company established in 2014 and located in Atlanta, Georgia. The company focuses on developing microneedle patches specifically for vaccines, including those for influenza and polio. Its innovative microneedle technology aims to improve protective and therapeutic effects while enhancing patient compliance and simplifying the administration process. By leveraging this technology, Micron Biomedical seeks to facilitate the development of effective vaccines, addressing important public health needs.

We are developing a global information exchange platform to accelerate the availability of safe and effective medicines.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Apriori Bio is a health security company dedicated to protecting humanity from viral threats. It employs a unique technology platform that surveys the landscape of existing and potential viral variants, enabling the design of variant-resilient vaccines and antibody drugs. By providing real-time insights, Apriori Bio aims to prepare for future outbreaks and ensure durable protection against rapidly evolving viruses. The company's innovative approach focuses on developing effective solutions to combat both current and emerging viral challenges.

BioNTech is a Germany-based biotechnology company that specializes in developing innovative immunotherapies for cancer and other serious diseases, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline includes a range of drug classes, such as mRNA-based drugs that encode antigens and neoantigens, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech has established partnerships with several major pharmaceutical companies, enhancing its research and development capabilities. Its COVID-19 vaccine, Comirnaty, represents its first commercialized product, demonstrating the company's commitment to addressing urgent health challenges through advanced therapeutic approaches.

aVaxziPen is a clinical-stage pharmaceutical company dedicated to developing innovative drug-device combination products, with a primary focus on next-generation vaccines targeting infectious diseases and emerging pathogens. The company employs its proprietary ImplaVax solid dose formulation and device technology to create novel solid dose vaccines aimed at addressing a variety of infectious and select diseases. By enhancing the performance and delivery of vaccines and therapeutics, aVaxziPen supports medical researchers in their efforts to advance these products to human clinical trials, thereby contributing to the overall progress in the field of vaccine development and infectious disease management.

Aspen Pharmacare Holdings Limited is a global specialty pharmaceutical company headquartered in Durban, South Africa. It manufactures and supplies a diverse portfolio of specialty, branded, and generic pharmaceutical products across more than 150 countries. The company operates through two main segments: Commercial Pharmaceuticals and Manufacturing. Aspen offers a range of products, including general anaesthetics, muscle relaxants, cytotoxic medicines, and injectable anticoagulants, with a focus on low molecular weight heparins. Additionally, Aspen engages in the contract manufacturing and supply of active pharmaceutical ingredients and finished dose pharmaceuticals for third parties. The company's extensive product offerings include oral solids, injectables, liquids, semi-solids, and biologicals. With a strong presence in various international markets, including Africa, Asia, Europe, and the Americas, Aspen continues to expand its operations through strategic acquisitions and partnerships. Founded in 1850, Aspen has established itself as a leading player in the pharmaceutical industry.

SK Bioscience is a South Korean pharmaceutical company focused on the development and manufacturing of vaccines. The company is notable for introducing SKYCellflu, the first cell culture influenza vaccine in Korea, and has since expanded its portfolio to include the SKYCellflu Quadrivalent prefilled syringe and a 13-valent Pneumococcal Conjugate Vaccine. In addition to these licensed products, SK Bioscience is actively engaged in the development of several other vaccines, including a recombinant rotavirus vaccine, a new typhoid conjugate vaccine, and an innovative pneumococcal vaccine, often in collaboration with external partners. The company is dedicated to building a robust infrastructure for continuous vaccine development, positioning itself as a key player in the global vaccine landscape.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

The Sabin Vaccine Institute is dedicated to enhancing vaccine accessibility and promoting immunization, particularly in low- and middle-income populations that are disproportionately affected by infectious diseases. The organization focuses on developing innovative vaccines aimed at preventing a wide range of illnesses, ensuring that these vital health resources are available to communities worldwide. By emphasizing the importance of immunization coverage, the Sabin Vaccine Institute seeks to improve overall healthcare outcomes and contribute to the prevention of diseases on a global scale.

NEC OncoImmunity AS is a bioinformatics company based in Oslo, Norway, specializing in machine-learning software solutions aimed at enhancing cancer immunotherapy. Founded in 2014 and a subsidiary of NEC Corporation since 2019, the company focuses on identifying immunogenic neoantigens to improve personalized cancer treatments. Its platform supports patient selection for immunotherapy by determining optimal neoantigen targets for personalized vaccines and cell therapies within a clinically actionable timeframe. By providing tools that address critical knowledge gaps, NEC OncoImmunity enables healthcare institutions and research organizations to advance the development of effective neoantigen-based immunotherapies and biomarkers for cancer treatment.

DIOSynVax is a vaccine antigen design company that focuses on accelerating vaccine development to enhance protection against both existing and emerging pathogens. By utilizing innovative technology, DIOSynVax digitally designs, optimizes, and synthesizes vaccines, leading to significant advancements in immunization against diseases such as influenza, COVID-19, and viral hemorrhagic fevers. The company's approach aims to improve the efficacy of vaccines, enabling healthcare professionals to treat patients more effectively and facilitate quicker recovery from various viral infections.

Clover Biopharmaceuticals is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative biologic therapies primarily targeting oncology and autoimmune diseases. The company employs its proprietary Trimer-Tag technology platform to create novel biologics that focus on trimerization-dependent pathways. In addition to its therapeutic efforts, Clover is also engaged in the development of select biosimilars, utilizing its in-house cGMP biomanufacturing capabilities. The company aims to address unmet medical needs in both infectious diseases and cancer through its advanced vaccine and therapeutic candidates.

Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan is a world leader in developing vaccines and technologies against infectious diseases.

MigVax Ltd. is an Israeli medical technology startup focused on the development, manufacture, and commercialization of vaccines targeting viruses affecting humans. Based in Kiryat Shmona, Israel, the company is a subsidiary of MIGAL - Galilee Research Institute LTD. MigVax is engaged in creating vaccines for various diseases, including a vaccine for the infectious bronchitis virus and others that address avian coronaviruses, which share similar infection mechanisms with human coronaviruses. This innovative approach enables medical practitioners to effectively combat a range of viral diseases.

Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.

Bharat Biotech Ltd. is a biotechnology company based in Hyderabad, India, specializing in the research, development, and manufacture of vaccines and biotherapeutics. Established in 1996, the company offers a diverse range of products, including vaccines such as Revac-B+, a recombinant hepatitis-B vaccine; TYPBAR, a typhoid vaccine; BIOPOLIO, a poliomyelitis vaccine; and INDIRAB, a rabies vaccine. Additionally, Bharat Biotech produces various biotherapeutics, like REGEN-D, a recombinant human epidermal growth factor gel for diabetic foot ulcers and burns, as well as treatments for osteoarthritis and other conditions. The company also provides women's healthcare products and has developed a cell culture H1N1 swine flu vaccine. Bharat Biotech exports its products to several countries, including Kenya, Zambia, and the Philippines, with a focus on creating affordable and effective therapies for neglected diseases.

Novavax Inc., established in 1987 and headquartered in Gaithersburg, Maryland, is a late-stage biotechnology company dedicated to discovering, developing, and commercializing vaccines to prevent serious infectious diseases worldwide. Its primary focus lies in advancing vaccine candidates through clinical trials, with notable projects including ResVax for RSV in infants via maternal immunization (Phase III), NanoFlu for seasonal influenza in older adults (Phase III), and NVX-CoV2373 for COVID-19 (preclinical). Novavax's proprietary Matrix-M adjuvant enhances immune response and enables lower antigen doses. The company collaborates globally to address urgent health needs, with Europe being its primary revenue source.

Inovio Pharmaceuticals, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and protecting individuals from diseases related to human papillomavirus (HPV), cancer, and infectious diseases. The company's innovative SynCon immunotherapy design enables the immune system to target cancerous cells while providing cross-strain protection against various pathogens. Inovio's clinical studies focus on HPV-associated precancers, cancers, and other disorders, as well as diseases such as glioblastoma multiforme, HIV, and COVID-19. The company has developed a proprietary delivery system that allows DNA medicine to be introduced directly into cells, producing a strong immune response. Notably, its lead candidate, VGX-3100, is undergoing Phase 3 trials for precancerous cervical dysplasia, having shown promise in earlier trials by effectively clearing high-risk HPV strains. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio collaborates with various partners, including major pharmaceutical companies and research institutions, to advance its clinical initiatives and expand its therapeutic reach.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Novavax Inc., established in 1987 and headquartered in Gaithersburg, Maryland, is a late-stage biotechnology company dedicated to discovering, developing, and commercializing vaccines to prevent serious infectious diseases worldwide. Its primary focus lies in advancing vaccine candidates through clinical trials, with notable projects including ResVax for RSV in infants via maternal immunization (Phase III), NanoFlu for seasonal influenza in older adults (Phase III), and NVX-CoV2373 for COVID-19 (preclinical). Novavax's proprietary Matrix-M adjuvant enhances immune response and enables lower antigen doses. The company collaborates globally to address urgent health needs, with Europe being its primary revenue source.

Inovio Pharmaceuticals, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and protecting individuals from diseases related to human papillomavirus (HPV), cancer, and infectious diseases. The company's innovative SynCon immunotherapy design enables the immune system to target cancerous cells while providing cross-strain protection against various pathogens. Inovio's clinical studies focus on HPV-associated precancers, cancers, and other disorders, as well as diseases such as glioblastoma multiforme, HIV, and COVID-19. The company has developed a proprietary delivery system that allows DNA medicine to be introduced directly into cells, producing a strong immune response. Notably, its lead candidate, VGX-3100, is undergoing Phase 3 trials for precancerous cervical dysplasia, having shown promise in earlier trials by effectively clearing high-risk HPV strains. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio collaborates with various partners, including major pharmaceutical companies and research institutions, to advance its clinical initiatives and expand its therapeutic reach.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.